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We examined prospectively the association between weight change during adulthood and breast cancer risk, using data on 1358
incident cases that developed during 5.8 years of follow-up among 40429 premenopausal and 57923 postmenopausal women from
six European countries, taking part in the European prospective investigation into cancer and nutrition study. Multivariate Cox
regression models were used to calculate hazard ratios according to weight change (kg), defined as the weight difference between
age at enrolment and age 20 adjusted for other risk factors. Changes in weight were not associated with premenopausal breast
cancer risk. In postmenopausal women, weight gain was positively associated with breast cancer risk only among noncurrent
hormone replacement therapy (HRT) users (P-trend p0.0002). Compared to women with a stable weight (72kg), the relative risk
for women who gained 15–20kg was 1.50 (95% confidence interval (CI) 1.06–2.13). The pooled RR per weight gain increment of
5kg was 1.08 (95% CI 1.04–1.12). Weight gain was not associated with breast cancer risk in current HRT users, although, overall,
these women experienced a much higher risk of breast cancer compared with nonusers. Our findings suggest that large adult weight
gain was a significant predictor of breast cancer in postmenopausal women not taking exogenous hormones.
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Weight gain during adult life, body weight, and fat distribution
may separately or in combination play a role in the development
and prognosis of breast cancer. The association between weight
change and breast cancer risk is modified by menopausal status,
with higher weight gain associated with decreased risk for
premenopausal women and increased risk for postmenopausal
women (IARC working group, 2002). More specifically, for
postmenopausal breast cancer risk, the most consistent body size
predictor appears to be weight gain, even in studies in which
general adiposity was only weakly associated with risk (Ziegler,
1997; Ballard-Barbash, 1999; Friedenreich, 2001; Willett, 2001).
Adult weight change is considered a dynamic body measure unlike
static measures such as body mass index (BMI), and has been
hypothesised to better reflect age-related metabolic changes that
may be important in breast cancer development (Ballard-Barbash,
1999). Relative risks between 1.2 and 2.3 for the highest vs lowest
categories for weight gained between age 18 or 20 and the reference
age were reported in previous case–control and cohort studies
(Friedenreich, 2001; IARC working group, 2002). However,
the data on weight change and breast cancer risk from prospective
studies are sparse, especially among premenopausal women.
Moreover, the potential effect modification by body size at
young adult age (Barnes-Josiah et al, 1995; Huang et al, 1997;
Magnusson et al, 1998; Weiderpass et al, 2004) or hormone
replacement therapy (HRT) use (Huang et al, 1997; Friedenreich
et al, 2002; Morimoto et al, 2002; Lahmann et al, 2003; Feigelson
et al, 2004) on the association between weight change and breast
cancer risk has been only investigated in a limited number of
studies.
The purpose of this study was to examine the association
between long-term adult weight change and risk of breast cancer in
pre- and postmenopausal women, controlling for other known risk
factors in female study participants from the European Prospective
Investigation into Cancer and Nutrition (EPIC). A secondary aim
of this study was to evaluate whether the association between
weight change and risk of breast cancer is modified by (a) initial
weight or BMI at age 20, and (b) current HRT use among
postmenopausal women.
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The EPIC is a multi-centre prospective cohort study designed
primarily to investigate the association between nutrition and
cancer. The EPIC cohort consists of 23 subcohorts in 10 European
countries: Denmark, France, Germany, Greece, Italy, The Netherlands,
Norway, Spain, Sweden, and the United Kingdom, thereby allowing
comparisons of lifestyle and food habits among regions with very
different cancer rates. Food-related and lifestyle questionnaires
were administered and anthropometric measurements obtained
from all participants at the time of enrolment (1992–2000). The
366521 eligible female participants were mostly aged 25–70 years
and recruited from the general population residing in a given
geographical area, such as a town or a province (Riboli et al, 2002).
Exceptions were the French cohort (health insurance scheme
for school employees), the Utrecht cohort in the Netherlands
(breast cancer screening attendees), the Ragusa cohort in Italy
(blood donors and their spouses), and the Oxford cohort in the
UK (based on vegetarian volunteers and healthy eaters). Eligible
subjects were invited to participate in the study, and those
who accepted gave informed consent and completed question-
naires on their diet, lifestyle and medical history. Study subjects
were then invited to a centre to provide a blood sample and to
have anthropometric measurements taken, methods of which
have been reported in full elsewhere (Riboli and Kaaks, 1997;
Riboli et al, 2002).
Study population
The present study was based on data from 345365 female
participants after excluding women with prevalent cancer at any
site at baseline examination, and those with missing nondietary
questionnaire data. The study population was further restricted to
125233 women from Denmark, Germany (Potsdam), Greece, Italy
(Varese), Sweden (Malmo ¨), and the United Kingdom, with
available data on recalled body weight at age 20 or 25 years, and
measured or predicted (Oxford, ‘health conscious group’) anthro-
pometric characteristics at study enrolment. Women were
classified according to menopausal status at enrolment based on
an algorithm as described elsewhere (Lahmann et al, 2004).
Accordingly, 33.1% of women were classified as premenopausal
and 47.7% were naturally postmenopausal. Women who were
perimenopausal (11.4%) or had a surgical menopause or uncertain
menopausal status (7.8%) were excluded from the present analysis.
Subjects with missing data on measured anthropometric char-
acteristics at enrolment and recalled weight at age 20, and women
aged 480 years at baseline were also excluded. The analytical
cohort for this study therefore consisted of 98352 women from six
countries, 40429 of whom were premenopausal and 57923 of
whom were naturally postmenopausal.
End points and ascertainment of cases
Incident breast cancer cases were identified through population
cancer registries (Denmark, Italy, Sweden, United Kingdom) or by
active follow-up (Germany, Greece), depending on the follow-up
systems in each of the participating countries. The active follow-up
procedure used a combination of methods including health
insurance records, cancer and pathology registries, and via contact
with participants and their next-of-kin. Women were followed
from study entry (1992–2000) until first breast cancer diagnosis,
death, emigration, or end of the follow-up period. By April 2004,
5984 breast cancer cases (invasive n¼5386; in situ n¼593;
unspecified n¼4; metastatic n¼1) had been reported to the
common database at the International Agency for Research on
Cancer (IARC), Lyon, based on information on complete follow-up
data up till December 2001 or December 2002 in most of the
centres. Mortality data were coded according to the 10th Revision
of the International Statistical Classification of Diseases, Injuries
and Causes of Death (ICD-10), and cancer incidence data were
coded according to ICD-O-2. This analysis included 1358 invasive
(primary, malignant) breast cancer cases, of which 264 occurred in
women who were premenopausal at recruitment and 1094 in
postmenopausal women.
Classification of body measures and other predictor
variables
Data on recalled weight at age 20 were available for cohorts in
Italy (Varese), United Kingdom, Greece, Sweden (Malmo ¨)a n d
Denmark, and for the age of 25 years in Germany (Potsdam). Weight
and height at recruitment were measured to the nearest 0.1kg and
0.1 or 0.5cm, respectively, with subjects wearing no shoes.
For the present study, baseline weight was adjusted to reduce
heterogeneity due to protocol differences in clothing worn during
measurement (Haftenberger et al, 2002). For the ‘health conscious
group’ in Oxford (UK), linear regression models were used to
predict sex- and age-specific values from women from the Oxford
general population group with both measured and self-reported
body measures (Haftenberger et al, 2002; Spencer et al, 2002).
Body mass index was calculated as weight in kg divided by height
in meters squared (kgm
 2). Subjects with a BMI of X25.0 to
o30.0kgm
 2 were classified as overweight and those with a BMI
of X30.0kgm
 2 were classified as obese (World Health Organiza-
tion, 1998). Adult weight change was calculated as the difference
between measured baseline weight at enrolment and recalled
weight at age 20 or 25 years.
Information on reproductive, sociodemographic, and lifestyle
characteristics was obtained from the standardised health ques-
tionnaire at study entry. Other known risk factors included in this
analysis were: age at menarche (p11, 12, 13, 14, 415 years), age at
first pregnancy (first birth o20, 20–30, 430 years, nulliparous),
education (none/primary school, technical/professional school,
secondary school, university), smoking status (never, former,
current), alcohol consumption as ethanol in gday
 1 (abstainers,
1–14, 15–30, 430g), leisure physical activity (continuous score),
height (continuous), current OC use (no/yes), and current
hormone use (no/yes). Current hormone use refers to the use of
menopausal hormones at the time of recruitment as derived from
the country-specific questionnaires or during interviews, and
includes oestrogen alone and combined oestrogen/progestin
preparations (referred to as HRT use).
Statistical analysis
Cox proportional hazards models were used to estimate adjusted
hazard ratios (HR) and 95% confidence intervals (CI) of breast
cancer incidence for each weight change category. Weight changes
were defined as follows:  2 and þ2kg as the referent category
(stable weight); more than  2kg as weight loss; and more than
þ2kg as weight gain. The latter was further divided into five
weight gain categories (2.1–5.0, 5.1–10.0, 10.1–15.0, 15.1–20.0,
420kg). Age was used as the underlying (primary dependent)
time variable in the counting process formulation, with entry time
t0 defined as the subject’s age at recruitment, and exit time t1
defined as the subject’s age at breast cancer diagnosis or censoring
date. All multivariate models were stratified (option ‘strata’ in SAS-
PHREG procedure) by age at recruitment and by study centre to be
less sensitive against violations of the proportional hazards
assumption, and simultaneously adjusted for the following
established or potential breast cancer risk factors: weight at age
20, height, leisure physical activity (as continuous variables), age at
menarche, parity, age at first birth, education, smoking status,
alcohol consumption, current OC use and current HRT use. An
indicator category for missing responses for each covariate was
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covariate data.
Trend tests were calculated on the basis of category-based
scores, assigning a score from 1 to 7 to an individual according to
the weight change categories. For country-specific analyses, weight
change was treated as categorical and continuous variable.
Potential effect modifications of the weight change–breast cancer
association were examined by (a) BMI at age 20 (dichotomised at
the median BMI for premenopausal women o/421.1kgm
 2, and
for postmenopausal women 21.3kgm
 2) and (b) current HRT use
(yes/no in postmenopausal women only). To test for interaction,
we used a metric score with median weight change within
categories of weight change as the exposure variable. All tests of
statistical significance were two-sided and P-values of o0.05 were
considered statistically significant. The statistical analyses were
performed with the use of the PHREG procedure in the Statistical
Analysis System (SAS) software package, version 9 (SAS Institute,
Cary, NC, USA).
RESULTS
In total, 98352 European women aged 20–80 years at baseline
were followed for an average of 5.8 (71.6) years and accrued a
total of 573102 person years. The median age at diagnosis was 49.0
years for premenopausal and 63.0 years for postmenopausal
women. Baseline characteristics are presented in Table 1. Among
premenopausal women, the median age at baseline varied
substantially across countries due to differences in enrolment
protocols between the EPIC centres. Details of other potential risk
factors across weight change categories are shown in Table 2.
Women with a stable weight between age 20 and study enrolment
were more likely to be nulliparous, current smokers, have a
university degree, and have had a higher body weight at age 20
than women who gained weight during adulthood (Table 2). On
average, 26.6% of postmenopausal women used HRT at baseline.
The proportion of both HRT users and OC users was smallest
among women with large weight gain. The percentage of smokers
was highest among women who lost weight over adulthood
(o 2kg).
Premenopausal women
Table 3 shows the mean weight at age 20 years, adult weight
change, weight, and BMI at enrolment in each of the participating
countries. Weight was recalled for age 20 in all cohorts except
Potsdam (Germany), where weight was recalled at age 25.
Premenopausal women from the UK were the heaviest at age 20,
and Italian women were the lightest. Subsequent adult weight gain
was smallest for the UK women and highest for the Danish women
(4.2 vs 12.1kg). This large difference can be in part attributed to
the different enrolment age. In all, 22% of premenopausal women
had lost weight between age 20 (25) and baseline examination. The
mean (s.d.) weight gain for the remaining women was 9.078.3kg.
At age 20, the prevalence of overweight (BMI 25–30) was 8.2%
and the prevalence of obesity (BMI X30) was 1.6%. At age of
enrolment, these prevalences had increased to 21.0 and 8.9%,
respectively.
Among premenopausal women, long-term weight gain was not
associated with breast cancer risk, irrespective of adjustment for
potential risk factors (Table 4). Weight loss of more than 2kg was
associated with a nonsignificant increased risk of about 50% in
each of the tested models. However, this may be due to the effect of
pre-existing disease, as, after excluding breast cancer cases
diagnosed during the first year of follow-up, the multivariate
adjusted risk estimate for weight loss approached unity (HR for
o 2kg: 1.01, CI 0.59–1.76 based on 175 cases), while relative
risks in the weight gain categories were not materially changed
(data not shown).
Initial weight or BMI at age 20 was inversely, but nonsignifi-
cantly associated with risk of breast cancer after adjustment for
relevant covariates (data not shown), and there was no evidence of
statistical interaction between BMI at age 20 and weight change in
relation to breast cancer risk.
Postmenopausal women
Similar to premenopausal women, for postmenopausal women, the
heaviest women at age 20 were from the UK and the lightest were
from Italy (Table 3). On average, postmenopausal women had a
weight gain of 11.0kg during adulthood, being smallest for the UK
Table 1 Cohort characteristics by menopausal status, the EPIC study
Premenopausal Postmenopausal
Country
Cohort
size (n)
a
Baseline age
median (range)
Person
years
No. of
cases
b
Cohort
size (n)
a
Baseline age
median (range)
Person
years
No. of
cases
b
Italy, Varese 2411 45 (37–57) 16783.1 43 2945 58 (41–78) 19997.2 65
UK 24515 36 (20–58) 132210.0 131 16635 61 (39–80) 89409.4 264
Cambridge 1510 48 (40–57) 7393.6 15 6243 63 (41–78) 32679.8 95
Oxford – GP
c 1373 45 (36–57) 9125.8 25 2241 57 (40–76) 14254.3 63
Oxford – HC
d 21632 34 (20–58) 115690.6 91 8151 60 (39–80) 42675.3 106
Greece 5107 40 (20–57) 19042.9 11 4431 61 (40–80) 16173.7 17
Germany, Potsdam 6320 40 (20–58) 37057.5 28 5492 59 (39–70) 33143.1 57
Sweden, Malmo — — — — 8459 61 (45–74) 62059.2 194
Denmark 2076 52 (50–58) 13654.4 51 19961 58 (50–66) 132871.6 497
Aarhus 766 51 (50–58) 4920.5 24 5749 58 (50–66) 37875.9 103
Copenhagen 1310 52 (50–58) 8733.9 27 14212 58 (50–66) 95495.7 394
Total 40429 39 (20–58) 218747.9 264 57923 59 (39–80) 354354.2 1094
aWomen with complete measured anthropometric characteristics at enrolment and recalled weight at age 20 (German cohort: age 25).
bInvasive (malignant, primary) breast
cancer.
cGP¼general population.
dHC¼health-conscious.
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of postmenopausal women had lost weight between age 20 and age
at study entry. The mean (s.d.) weight gain for the remaining
women was 13.579.5kg. Hormone replacement therapy users had
a smaller mean change in weight than those not taking hormones
(10.079.4 and 11.7711.4kg, respectively). At age 20, the
proportion of women who were overweight and obese was very
similar to that of premenopausal women, although at the age of
enrolment the prevalence of overweight (35.2%) and obesity
(16.5%) in postmenopausal women was much higher than that of
premenopausal women.
Among postmenopausal women overall, there was a positive
trend between adult weight gain and breast cancer risk in all of the
tested models, although none of the individual categorical risk
estimates reached statistical significance (multivariate adjusted HR
by weight change category: 0.75 (CI 0.54, 1.04); 1.0 (reference); 0.98
(CI 0.74, 1.29); 1.01 (CI 0.80, 1.28); 1.00 (CI 0.78, 1.27); 1.12 (CI
0.87, 1.45); 1.22 (CI 0.96, 1.56); trend P¼0.002). Only after
stratification by current HRT use, stronger positive associations
between weight gain and breast cancer became apparent among
women not currently using HRT at recruitment, and the
interaction term between HRT use and weight change approached
statistical significance (P¼0.10) (Table 5). Compared to women in
the reference group (72kg), women in the upper two categories of
weight gain between 15–20kg and 420kg had excess risks of 50
and 52%, respectively, after adjusting for multiple covariates.
Among current HRT users, weight gain was not significantly
associated with breast cancer risk. Further adjustment for age at
menopause (data were available for 87% of the subjects) did not
substantially alter the results in nonusers or HRT users. The
omission of the first year of follow-up did not substantially alter
these associations (data not shown).
Figure 1 shows the relative risk estimates when comparing each
combined weight change–HRT use category with a uniform
reference category (non-HRT user with stable weight72kg).
Among nonusers, multivariate adjusted relative risks were
Table 2 Frequency distribution and mean values of covariates across weight change categories in pre- and postmenopausal women, n¼98352, the EPIC
study
Characteristic
a
o 2kg
(n¼9848)
72kg
(n¼14411)
2–5kg
(n¼13378)
5–10kg
(n¼21055)
10–15kg
(n¼15989)
15–20kg
(n¼10365)
20+ kg
(n¼13306)
%
Age at menarche
o12 years 14.6 13.6 13.2 13.6 13.3 13.1 14.6
12 years 18.4 19.5 19.5 18.9 18.6 18.5 18.6
13 years 25.9 27.3 27.0 25.1 24.6 23.7 22.7
14 years 21.0 21.5 21.5 22.7 22.8 22.7 21.1
15+ years 18.5 16.8 17.2 18.1 19.2 20.3 20.3
Age at first birth
o20 years 5.0 4.7 5.5 7.3 8.9 10.2 12.2
20–30 years 47.9 46.0 54.5 60.9 65.8 66.5 66.5
30+ years 12.0 11.6 12.5 12.7 10.7 10.4 9.7
Nulliparous 33.6 36.2 26.2 18.6 13.7 12.1 10.5
Education
Primary school or
less
18.3 12.8 15.8 21.2 27.9 33.8 42.7
Technical school 27.3 26.6 30.4 32.2 33.0 32.2 28.8
Secondary school 15.5 18.1 14.8 14.5 14.0 12.8 11.1
University degree 30.9 35.6 32.0 24.3 17.9 14.6 11.8
Alcohol consumption
Nondrinker 8.2 6.0 6.1 7.3 9.0 11.5 15.4
0–15gday
 1 76.1 77.6 77.1 74.8 73.0 71.9 70.5
15–30gday
 1 10.1 11.2 11.0 11.3 11.1 10.1 8.2
430gday
 1 5.6 5.2 5.8 6.6 7.0 6.5 5.9
Smoking status
Never smokers 52.1 58.9 57.0 56.1 55.1 55.5 59.1
Former smokers 22.0 21.0 23.4 24.6 25.5 25.8 24.0
Current smokers 25.2 19.2 18.9 18.4 18.5 17.6 16.0
Current HRT use
b
Yes 24.1 27.8 30.7 30.9 28.4 24.5 19.0
Current oral contraceptive use
c
Yes 16.5 21.0 18.0 14.0 9.5 7.1 3.9
Mean (s.d.)
Weight at age 20
d (kg) 64.1 (10.2) 57.5 (7.3) 56.6 (6.9) 56.1 (7.1) 55.8 (7.5) 55.7 (7.9) 56.2 (9.0)
Height, cm 163.0 (6.5) 163.4 (6.5) 163.1 (6.4) 162.6 (6.4) 162.3 (6.5) 162.2 (6.6) 162.0 (6.7)
Leisure physical activity
(score)
863 (456) 840 (452) 855 (454) 865 (455) 859 (452) 859 (458) 855 (466)
aNumbers within each weight change category do not add up to 100% due to missing values.
bPostmenopausal women.
cPremenopausal women.
dRecalled weight at age 20
years, except for German cohort (recalled weight at age 25 years).
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respectively, compared with women with stable weight. Overall,
HRT users experienced a much higher breast cancer risk compared
to non-users, irrespective of their change in weight.
Similar to premenopausal women, initial weight and BMI at age
20 were inversely, but nonsignificantly, associated with risk of
postmenopausal breast cancer both before and after adjustment
for weight change or other covariates (data not shown). There was
no evidence of a significant interaction between BMI at age 20
(o/421.3kgm
 2) and weight change in relation to breast cancer
risk irrespective of HRT use.
Figure 2 shows the multivariate adjusted risk estimates for
breast cancer in relation to continuous weight change by 5kg for
all cohorts combined and for individual countries with at least 30
cases of breast cancer, stratified by menopausal status and HRT
use. Similar to the categorical analyses, there was no association
between weight change and breast cancer in premenopausal
women or among postmenopausal women using HRT. Among
postmenopausal women not using HRT, for one increment of
weight change (5kg), the pooled HR was 1.08 (CI 1.04–1.12), with
a P-value for linear trend of o0.0001. No evidence of heterogeneity
between countries was present for any of the presented analyses.
DISCUSSION
In this large cohort of women from six European countries, aged
20–80 years at study enrolment, increased weight gain was
significantly associated with excess breast cancer risk in post-
menopausal, but not in premenopausal, women, independent of
other potential risk factors.
Our finding of a nonsignificant inverse association between
weight gain and premenopausal breast cancer risk is in line with
evidence from the few studies that have examined this (Le
Marchand et al, 1988; Brinton and Swanson, 1992; Huang et al,
1997; Coates et al, 1999; Peacock et al, 1999; Friedenreich et al,
2002; Weiderpass et al, 2004). Most of these studies report a risk
reduction of about 30% for women in the highest weight change or
BMI change category compared to women in the reference group
with low weight gain or stable weight. However, in contrast to
Table 3 Mean recalled weight at age 20 years, adult weight change, baseline weight and body mass index in 98352 women by menopausal status and
study centre, the EPIC study
Premenopausal (n¼40429) (mean (s.d.)) Postmenopausal (n¼57923) (mean (s.d.))
Country
Weight at age
20 years (kg)
Weight
change (kg) Weight (kg) BMI (kgm
 2)
Weight at age
20 years (kg)
Weight change
(kg) Weight (kg) BMI (kgm
 2)
Italy, Varese 52.8 (7.9) 9.8 (10.1) 62.6 (11.2) 24.9 (4.3) 52.6 (7.4) 12.2 (11.0) 64.8 (11.0) 26.3 (4.4)
UK 58.4 (8.6) 4.2 (8.3) 62.6 (10.9) 23.0 (3.8) 57.1 (7.8) 8.6 (10.0) 65.7 (11.4) 25.3 (4.2)
Cambridge 57.0 (7.9) 8.5 (9.1) 65.5 (12.3) 24.7 (4.4) 56.5 (7.7) 9.7 (10.0) 66.2 (11.3) 25.8 (4.2)
Oxford – GP
a 58.0 (8.5) 8.0 (10.9) 66.0 (13.7) 24.8 (5.1) 57.0 (7.8) 9.8 (10.7) 66.8 (12.7) 25.5 (4.7)
Oxford – HC
b 58.5 (8.7) 3.7 (7.8) 62.2 (10.5) 22.7 (3.6) 57.5 (7.8) 7.5 (9.6) 65.0 (11.1) 24.8 (4.0)
Greece 56.7 (8.1) 11.0 (11.3) 67.7 (13.0) 26.5 (5.1) 55.7 (9.9) 15.7 (13.8) 71.3 (12.3) 29.7 (5.1)
Germany, Potsdam
c 59.4 (8.9) 6.8 (8.4) 66.2 (12.4) 24.5 (4.4) 58.9 (8.1) 11.6 (10.4) 70.5 (12.5) 27.0 (4.6)
Sweden, Malmo ¨ — — — — 55.6 (7.2) 11.7 (10.7) 67.3 (11.8) 25.4 (4.3)
Denmark 57.0 (7.4) 12.1 (10.2) 69.1 (11.9) 25.2 (4.2) 56.6 (7.6) 11.9 (10.7) 68.5 (12.1) 25.5 (4.3)
Aarhus 57.2 (7.4) 11.6 (10.1) 68.8 (11.6) 25.2 (4.1) 56.3 (7.5) 11.7 (10.7) 68.0 (11.7) 25.4 (4.2)
Copenhagen 56.9 (7.4) 12.3 (10.3) 69.2 (12.1) 25.1 (4.2) 56.7 (7.6) 12.0 (10.7) 68.7 (12.2) 25.6 (4.4)
Total 57.9 (8.6) 6.2 (9.4) 64.1 (11.7) 23.9 (4.3) 56.5 (7.9) 11.2 (10.9) 67.7 (12.0) 25.9 (4.5)
aGP¼general population.
bHC¼health-conscious.
cRecalled weight at age 25.
Table 4 Hazard ratio estimates of breast cancer by weight change categories in 40429 premenopausal women, the EPIC Study
HR (95% CI)
Weight change category Number of cases Model 1 Model 2 Model 3
o 2kg 34 1.37 (0.86, 2.18) 1.51 (0.94, 2.45) 1.56 (0.96, 2.54)
Ref ‘72kg’ 37 1.00 1.00 1.00
2.1–5kg 41 1.10 (0.70, 1.72) 1.08 (0.69, 1.69) 1.09 (0.70, 1.70)
5.1–10kg 45 0.92 (0.61, 1.41) 0.91 (0.59, 1.38) 0.91 (0.59, 1.38)
10.1–15kg 49 1.21 (0.78, 1.87) 1.19 (0.77, 1.85) 1.20 (0.77, 1.87)
15.1–20kg 24 1.00 (0.59, 1.69) 0.99 (0.58, 1.67) 1.00 (0.59, 1.71)
420kg 24 0.85 (0.50, 1.44) 0.86 (0.51, 1.47) 0.87 (0.51, 1.49)
P for trend 0.241 0.1732 0.1850
Model 1: stratified by centre and age at recruitment. Model 2: stratified by centre and age at recruitment, adjusted for weight at age 20. Model 3: stratified by centre and age at
recruitment, adjusted for weight at age 20, age at menarche, age at first birth/parity, OC use, education, height, alcohol intake, smoking status, and leisure physical activity.
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weight loss since age 20 was not significantly associated with
excess risk in the present study, specifically after excluding the first
year of follow-up, which suggests that this association found in
other studies may have been a reflection of pre-existing disease.
The biological mechanisms linking adiposity to premenopausal
breast cancer risk are not fully understood. There is some evidence
that overweight premenopausal women have more irregular and
anovulatory menstrual cycles, and hence less cumulative exposure
to oestrogen and progesterone, which reduces breast cancer risk
(Stoll, 1997; IARC working group, 2002). Notably, the exclusion of
women with reported irregular menses and/or infertility did not
affect the association between adult BMI and premenopausal
breast cancer risk in a Scandinavian cohort (Weiderpass et al,
2004), and low luteal phase serum progesterone levels were
associated with higher, and not lower, breast cancer risk in an
Italian cohort (Micheli et al, 2004). Further clarification is needed
with regard to the underlying mechanisms of the inverse body
size–breast cancer association before the menopause.
Table 5 Hazard ratio estimates of breast cancer by weight change categories stratified by current HRT use in postmenopausal women, the EPIC Study
HR (95% CI)
Weight change category Number of cases Model 1 Model 2 Model 3
Non-HRT user (n¼41969)
o 2kg 35 0.83 (0.53, 1.29) 0.79 (0.51, 1.24) 0.79 (0.50, 1.24)
Ref ‘72kg’ 47 1.00 1.00 1.00
2.1–5kg 60 1.17 (0.80, 1.72) 1.18 (0.81, 1.74) 1.19 (0.81, 1.75)
5.1–10kg 127 1.25 (0.90, 1.76) 1.27 (0.91, 1.78) 1.27 (0.90, 1.78)
10.1–15kg 110 1.16 (0.82, 1.64) 1.18 (0.84, 1.67) 1.18 (0.84, 1.67)
15.1–20kg 104 1.49 (1.05, 2.10) 1.51 (1.07, 2.14) 1.50 (1.06, 2.13)
420kg 143 1.52 (1.09, 2.12) 1.54 (1.10, 2.15) 1.52 (1.08, 2.13)
P for trend 0.0001 0.0001 0.0002
HRT user (n¼15186)
o 2kg 27 0.71 (0.44, 1.13) 0.74 (0.46, 1.19) 0.77 (0.47, 1.24)
Ref ‘72kg’ 51 1.00 1.00 1.00
2.1–5kg 51 0.79 (0.53, 1.17) 0.78 (0.53, 1.16) 0.79 (0.53, 1.17)
5.1–10kg 106 0.80 (0.57, 1.13) 0.79 (0.57, 1.11) 0.79 (0.56, 1.10)
10.1–15kg 97 0.86 (0.61, 1.21) 0.84 (0.59, 1.19) 0.82 (0.58, 1.17)
15.1–20kg 56 0.79 (0.54, 1.16) 0.78 (0.53, 1.14) 0.76 (0.51, 1.13)
420kg 68 0.95 (0.66, 1.37) 0.94 (0.65, 1.36) 0.95 (0.65, 1.38)
P for trend 0.590 0.7525 0.8660
Model 1: stratified by centre and age at recruitment. Model 2: stratified by centre and age at recruitment, adjusted for weight at age 20. Model 3: stratified by centre and age at
recruitment, adjusted for weight at age 20, age at menarche, age at first birth/parity, education, height, alcohol intake, smoking status, and leisure physical activity.
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Figure 1 Multivariate adjusted HR of breast cancer by weight change
category and current HRT use in postmenopausal women (n¼57923),
the EPIC study.
Figure 2 Country-specific and pooled multivariate adjusted HR of breast
cancer by menopausal status and HRT use for weight change (5kg)
(country-specific risk estimates are only presented for countries with 30 or
more cases), the EPIC study.
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association varied by HRT use. The examination of the modifying
effect of HRT on the weight change–breast cancer association
using a common reference group indicated that the increase in risk
by weight gain was clearly evident in women not using HRT.
Among current HRT users who have a much higher risk of
developing breast cancer, there was no association between adult
weight gain and cancer risk.
The effect of HRT use on the association between weight change
and breast cancer risk has been previously reported (Huang et al,
1997; Friedenreich et al, 2002; Morimoto et al, 2002; Feigelson
et al, 2004). The relative risk estimates in the current analysis are
lower than those found in the Nurses’ Health Study among women
who never used hormones (Huang et al, 1997), but similar to those
observed in the Cancer Prevention Study (CPS)-II Nutrition cohort
for comparable weight categories (Feigelson et al, 2004). The
pooled estimates in the present study indicate that the risk per 5kg
weight gained among women not using exogenous hormones
increased by 8%, which is in line with a report from a Swedish
case–control study, where the excess risk per 5kg was 7% among
non-users of HRT (Magnusson et al, 1998).
Our finding lends support to the hypothesis that adiposity
increases breast cancer risk through its oestrogenic effects (Key
et al, 2001). Weight gain during adult life mainly reflects the
deposition of fat mass rather than lean body mass. After
menopause, adipose tissue is the major location for the synthesis
of oestrogens from androgenic precursors (Siiteri, 1987; Bray,
2002). Accordingly, the increased risk of breast cancer in
postmenopausal women who gain large amounts of weight or are
overweight is attributed to excess plasma levels of oestrogens,
together with low levels of sex-hormone-binding globulin (SHBG)
(Stoll, 1994; Thomas et al, 1997; Endogenous Hormones and Breast
Cancer Collaborative Group, 2003; Calle and Kaaks, 2004). Use
of HRT can obscure the effect of adiposity on breast cancer risk
by influencing circulating oestrogen levels; therefore, stratified
analyses have been applied in recent studies. The present study
found that weight change was not associated with breast cancer
risk among current HRT users, which is consistent with previous
studies (Harris et al, 1992; Huang et al, 1997; Magnusson et al,
1998; Morimoto et al, 2002; Feigelson et al, 2004) and may be
attributable to the higher oestrogen levels from hormone therapy
than those derived from adipose tissue (Hankinson et al, 1998;
Trentham-Dietz et al, 2000). Whether the small risk reduction
observed with increasing weight gain among HRT users in our
study is real or due to chance finding remains to be explored in
future studies.
It has been proposed that a high BMI in early adult life may
influence cancer risk in later life and the potential effect
modification by early body size on the association between weight
change and breast cancer risk has been previously investigated
(Barnes-Josiah et al, 1995; van der Brandt et al, 1997). In the
present analysis, body weight at age 20 did not modify the weight
change–breast cancer association in postmenopausal hormone
users or non-users, which is consistent with the CPS-II Study
(Feigelson et al, 2004).
Some limitations of these data should be noted. Our
conclusions are based on results derived from a large cohort
(cases n¼1358), but with a limited follow-up period (5.8 years).
Re-examination of our data after the removal of pre-
existing disease by excluding individuals diagnosed during
the first year of follow-up did not materially change the main
findings, but did attenuate the association between weight loss
and breast cancer risk among premenopausal women. Extended
follow-up will allow us to evaluate the effect of excluding
likely pre-existing disease with more confidence. Furthermore,
it cannot be ruled out that some confounding bias is still present,
due to the lack of inclusion of other unknown potential risk
factors.
We were unable to evaluate in more detail the effect of weight
gain at different ages, other than that of weight at age 20 and
weight at enrolment. To date, only a few studies have been able to
disentangle the effects of weight at different ages vs weight gain
over a lifetime, indicating no differential effect on breast cancer
risk (Trentham-Dietz et al, 1997; Morimoto et al, 2002; Radimer
et al, 2004), or the tendency that weight gained after age 50 confers
an increased risk (Friedenreich et al, 2002). A further limitation is
that weight at age 20 was based on self-reported recall. However,
evidence suggests that past body weight is reported with reason-
able accuracy in comparison with measured past weight among
elderly (Stevens et al, 1990) and middle-aged adults (Casey et al,
1991), even when recalled up to 30 years later. A major strength of
this study is that all body measures assessed at enrolment were
directly measured in a standardised way, in contrast to the self-
reported data used in the majority of previous studies. Thus,
nondifferential misclassification of baseline weight should be
minimal.
In conclusion, these results show that large weight gain among
postmenopausal women who do not use HRT is associated with an
increased risk of breast cancer. Among current HRT users, who
overall are at a higher risk of breast cancer than non-HRT users,
weight gain is not associated with risk. These data provide further
support for the positive association of adiposity with breast cancer
among postmenopausal women. As obesity has reached epidemic
proportions and is also a modifiable lifestyle factor, avoidance of
weight gain throughout life is a salient measure for prevention of
breast cancer.
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